AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28655901 — intervention group
Group type: COMPARATOR
Intervention: Rested state (3 weeks of 8 hours time in bed per night)
Number of subjects: 0
Study 25994905 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBV)
Number of subjects: 25
Study 23364814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa polyphenols (500 mg)
Number of subjects: 72
Study 23364814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa polyphenols (250 mg)
Number of subjects: 72
Study 23364814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 72
Study 21854625 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg
Number of subjects: 60
Study 21854625 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study 18188136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) exercise program
Number of subjects: 64
Study 16564292 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylcholine-coated CPB system
Number of subjects: 28
Study 16564292 — intervention group
Group type: COMPARATOR
Intervention: Uncoated CPB system (Control)
Number of subjects: 28
Study 12656907 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg every 12 hours plus Vitamin E 600 mg/day for 6 months
Number of subjects: 45
Study 12656907 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg/day for 6 months
Number of subjects: 45
Study 11252642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium therapy
Number of subjects: 0
Study 11252642 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate and carbamazepine
Number of subjects: 0
Study 11252642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine and related dihydropyridine calcium channel blockers
Number of subjects: 0
Study 11252642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine, gabapentin, topiramate, atypical neuroleptics
Number of subjects: 0
Study 11252642 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimodal antidepressants
Number of subjects: 0
Study 8820469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate 25, 50, 100, 150, or 200 mg
Number of subjects: 40
Study 8820469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1595343 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 100 micrograms/kg
Number of subjects: 24
Study 1595343 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 24
Study 6475177 — intervention group
Group type: EXPERIMENTAL
Intervention: teopranitol (KC 046) 0.04 mg/kg body weight
Number of subjects: 10
Study 6475177 — intervention group
Group type: COMPARATOR
Intervention: untreated patients with coronary heart disease
Number of subjects: 10
Study 31586022 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (weekly subcutaneous injections)
Number of subjects: 31
Study 29577710 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing with Low Level Laser Therapy (LLLT)
Number of subjects: 30
Study 29577710 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 30
Study 27354368 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 µg GI.1 VLP and 50 µg GII.4 VLP (15/50 formulation)
Number of subjects: 454
Study 27354368 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µg GI.1 VLP and 50 µg GII.4 VLP (50/50 formulation)
Number of subjects: 454
Study 27354368 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 454
Study 24573567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-source high-pitch CTA
Number of subjects: 20
Study 24573567 — intervention group
Group type: COMPARATOR
Intervention: Single-source standard-pitch CTA
Number of subjects: 20
Study 23013243 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal T2D genetic risk score (T2DGRS)
Number of subjects: 0
Study 23013243 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and offspring fasting glucose genetic risk score (FGGRS)
Number of subjects: 0
Study 23013243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose plasma measurements
Number of subjects: 0
Study 20562074 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus eluting stent (BES)
Number of subjects: 1707
Study 20562074 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus eluting stent (SES)
Number of subjects: 1707
Study 17594068 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment for abdominal aneurysms
Number of subjects: 0
Study 17594068 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery for abdominal aneurysms
Number of subjects: 0
Study 17594068 — intervention group
Group type: EXPERIMENTAL
Intervention: New endovascular procedures for thoracic aorta
Number of subjects: 0
Study 17594068 — intervention group
Group type: COMPARATOR
Intervention: Endovascular procedures
Number of subjects: 0
Study 15766301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 369
Study 15766301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 11295900 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises
Number of subjects: 27
Study 11295900 — intervention group
Group type: COMPARATOR
Intervention: Back schools
Number of subjects: 27
Study 11295900 — intervention group
Group type: COMPARATOR
Intervention: Lumbar supports
Number of subjects: 27
Study 11295900 — intervention group
Group type: COMPARATOR
Intervention: Ergonomic interventions
Number of subjects: 27
Study 11295900 — intervention group
Group type: COMPARATOR
Intervention: Risk factor modification
Number of subjects: 27
Study 9589514 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane phospholipid hypothesis as a biochemical basis for schizophrenia
Number of subjects: 0
Study 7941199 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia and caudal nerve block
Number of subjects: 77
Study 7941199 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia and local nerve block
Number of subjects: 77
Study 7941199 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 77
Study 7941199 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal nerve block
Number of subjects: 77
Study 7941199 — intervention group
Group type: EXPERIMENTAL
Intervention: Local nerve block
Number of subjects: 77
Study 2975095 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (0.5 mg)
Number of subjects: 30
Study 2975095 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (2 mg)
Number of subjects: 30
Study 29298255 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture Button (SB)
Number of subjects: 97
Study 29298255 — intervention group
Group type: COMPARATOR
Intervention: Single Syndesmotic Screw (SS)
Number of subjects: 97
Study 28774339 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate depression education intervention
Number of subjects: 150
Study 28774339 — intervention group
Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 150
Study 26635906 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation classifier comprised of 22 CpG islands
Number of subjects: 226
Study 26635906 — intervention group
Group type: COMPARATOR
Intervention: Cancer-free control subjects
Number of subjects: 226
Study 23841267 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingjie Tongluo Recipe (QTR) plus external washing of Chinese herbs plus external dressing by herbs
Number of subjects: 60
Study 23841267 — intervention group
Group type: COMPARATOR
Intervention: Routine aseptic external dressing
Number of subjects: 60
Study 23841267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after treatment)
Number of subjects: 60
Study 20929990 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 371
Study 20929990 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 371
Study 20929990 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 371
Study 20929990 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (rosiglitazone, metformin, and any insulin)
Number of subjects: 371
Study 19301513 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (0.3% triclosan/2.0% PVM/MA copolymer/sodium fluoride in a 17% dual silica base)
Number of subjects: 33
Study 19301513 — intervention group
Group type: COMPARATOR
Intervention: Positive Control Dentifrice (0.3% triclosan/2.0% PVM/MA copolymer/sodium fluoride in a 10% high-cleaning silica base)
Number of subjects: 33
Study 19301513 — intervention group
Group type: COMPARATOR
Intervention: Negative Control Dentifrice (0.243% sodium fluoride in a regular silica base)
Number of subjects: 33
Study 17212893 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia (0.25% bupivacaine with epinephrine) infiltrated into abdominal wall wounds at suture fixation sites
Number of subjects: 18
Study 17212893 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia (control group)
Number of subjects: 18
Study 12704485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist services (intervention group)
Number of subjects: 80
Study 12704485 — intervention group
Group type: COMPARATOR
Intervention: Usual care from clinic staff (nonintervention group)
Number of subjects: 80
Study 10585345 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex method for hs-CRP measurement
Number of subjects: 288
Study 10585345 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA method for hs-CRP measurement
Number of subjects: 288
Study 8915969 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 840
Study 8915969 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict blood pressure control (mean arterial pressure reduction)
Number of subjects: 840
Study 8915969 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting treatment with diuretics
Number of subjects: 840
Study 8915969 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting treatment with beta-blockers
Number of subjects: 840
Study 8915969 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting treatment with angiotensin-converting enzyme inhibitors
Number of subjects: 840
Study 1918302 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (Norditropin, Novo Nordisk Gentofte A/S) 24 IU intramuscular injections on alternate days
Number of subjects: 20
Study 1918302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6225984 — intervention group
Group type: EXPERIMENTAL
Intervention: spectinomycine 2 g
Number of subjects: 636
Study 6225984 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin + probenecide 3.5 g + 1 g
Number of subjects: 636
Study 6225984 — intervention group
Group type: EXPERIMENTAL
Intervention: thiamphenicol 2.5 g
Number of subjects: 636
Study 6225984 — intervention group
Group type: EXPERIMENTAL
Intervention: minocycline 300 mg
Number of subjects: 636
Study 29177461 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials for evaluating treatments and vaccines during the Ebola epidemic
Number of subjects: 0
Study 29177461 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved planning and collaboration among research and humanitarian organizations
Number of subjects: 0
Study 27009916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sifalimumab 200 mg
Number of subjects: 431
Study 27009916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sifalimumab 600 mg
Number of subjects: 431
Study 27009916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sifalimumab 1200 mg
Number of subjects: 431
Study 27009916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 27009916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sifalimumab (all dosages)
Number of subjects: 431
Study 27009916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sifalimumab
Number of subjects: 431
Study 24756514 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (up to 4 g/d) with low-sodium weight-reduction diet
Number of subjects: 165
Study 24756514 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low-sodium weight-reduction diet
Number of subjects: 165
Study 22789509 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotarix (rotavirus vaccine)
Number of subjects: 101
Study 22789509 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivotif (typhoid vaccine)
Number of subjects: 101
Study 22789509 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAM2017 (candidate vaccine against ETEC)
Number of subjects: 101
Study 22789509 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 101
Study 20530499 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate/magnesium carbonate (CaMg)
Number of subjects: 326
Study 20530499 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride (HCl)
Number of subjects: 326
Study 18198169 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly Recovery Management Checkups (RMCs)
Number of subjects: 865
Study 16132334 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 252
Study 16132334 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 252
Study 12749494 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0
Study 12749494 — intervention group
Group type: COMPARATOR
Intervention: Control areas (lacking ITNs)
Number of subjects: 0
Study 10521553 — intervention group
Group type: EXPERIMENTAL
Intervention: Post infectious encephalomyelitis patients
Number of subjects: 11
Study 10521553 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI follow-up
Number of subjects: 11
Study 10521553 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinical and MRI pattern
Number of subjects: 11
Study 8750154 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU 400 mg/m2/d and FA 200 mg/m2/d i.v. on days 1‐5, TP‐5 50 mg s.c. on days 8‐11, and IL‐2 9 MU/m2 s.c. twice daily on days 12‐16
Number of subjects: 45
Study 8750154 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU + FA + TP‐5 + IL‐2
Number of subjects: 45
Study 8750154 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU + FA
Number of subjects: 45
Study 1902657 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 0
Study 1902657 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid solutions
Number of subjects: 0
Study 7470682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry spirometer (DS)
Number of subjects: 28
Study 6681970 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release furosemide (Eutensin) 40 mg
Number of subjects: 6
Study 6681970 — intervention group
Group type: COMPARATOR
Intervention: Furosemide tablets (Lasix) 40 mg
Number of subjects: 6
Study 6681970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 6
Study 31303479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention
Number of subjects: 489
Study 31303479 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 489
Study 31303479 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline responses to PATD and BMQ-Specific items
Number of subjects: 489
Study 29924809 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Implicit Association Test (BIAT) for implicit motives measurement
Number of subjects: 0
Study 26507118 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuotemporal cues during walking training
Number of subjects: 32
Study 26507118 — intervention group
Group type: COMPARATOR
Intervention: No visuotemporal cues during walking training
Number of subjects: 32
Study 25349362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilmicosin at 10 mg/kg BW (TIL)
Number of subjects: 2336
Study 25349362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulathromycin at 2.5 mg/kg BW (TUL)
Number of subjects: 2336
Study 25349362 — intervention group
Group type: COMPARATOR
Intervention: No metaphylactic treatment (ND)
Number of subjects: 2336
Study 25349362 — intervention group
Group type: EXPERIMENTAL
Intervention: Steers pulled for BRD
Number of subjects: 2336
Study 22945707 — intervention group
Group type: EXPERIMENTAL
Intervention: MBT technique
Number of subjects: 30
Study 22945707 — intervention group
Group type: COMPARATOR
Intervention: ROTH philosophy
Number of subjects: 30
Study 20298120 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antioxidants (single or double dose)
Number of subjects: 60
Study 20298120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19298018 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin and tranexamic acid (TA) administered to selected patients in the study group of 133 patients.
Number of subjects: 221
Study 19298018 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group of 82 patients who did not receive TA).
Number of subjects: 221
Study 15999571 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics intervention (consultant‐guided six‐step approach)
Number of subjects: 118
Study 15999571 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory ergonomics intervention
Number of subjects: 118
Study 15999571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 118
Study 12063869 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin and synthetic analogues (octreotide)
Number of subjects: 0
Study 11220531 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular junctional ablation and DDDR mode-switching pacemaker implantation
Number of subjects: 43
Study 11220531 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment
Number of subjects: 43
Study 7854375 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 843
Study 7854375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 843
Study 7854375 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine
Number of subjects: 843
Study 7854375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone (50 mg)
Number of subjects: 843
Study 7854375 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 843
Study 1776338 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (2 x 8 mg/d)
Number of subjects: 393
Study 1776338 — intervention group
Group type: COMPARATOR
Intervention: ASA (1 x 500 mg/d) plus nifedipine (3 x 20 mg/d)
Number of subjects: 393
Study 7014183 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (Cerucal, 10 mg i.v. or p.o.)
Number of subjects: 14
Study 31791892 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside-In retrograde drilling (OI)
Number of subjects: 72
Study 31791892 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial Portal with Flexible reamer (AMP-FR)
Number of subjects: 72
Study 31791892 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtibial (TT)
Number of subjects: 72
Study 31791892 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial Portal with Rigid reamer (AMP-RR)
Number of subjects: 72
Study 31791892 — intervention group
Group type: COMPARATOR
Intervention: Control group (intact native ACL)
Number of subjects: 72
Study 30343563 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel®
Number of subjects: 0
Study 30343563 — intervention group
Group type: COMPARATOR
Intervention: LMA SupremeTM
Number of subjects: 0
Study 28509727 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers (CCBs)
Number of subjects: 1951
Study 28509727 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers (ARBs)
Number of subjects: 1951
Study 28509727 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers (CCBs) in participants without a history of cardiovascular disease
Number of subjects: 1951
Study 28509727 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers (CCBs) in participants with uncontrolled hypertension
Number of subjects: 1951
Study 28509727 — intervention group
Group type: COMPARATOR
Intervention: Any other antihypertensive medication (Control)
Number of subjects: 1951
Study 25272094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75-600 mg/d for DPN, 150-600 mg/d for PHN)
Number of subjects: 4527
Study 25272094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4527
Study 24129974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab, and docetaxel
Number of subjects: 808
Study 24129974 — intervention group
Group type: COMPARATOR
Intervention: Placebo, trastuzumab, and docetaxel
Number of subjects: 808
Study 21704965 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05%
Number of subjects: 52
Study 21704965 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 52
Study 18357434 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition supplemented with fish oil (n-3/n-6 ratio of 1:2)
Number of subjects: 166
Study 18357434 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition (n-3/n-6 ratio of 1:7)
Number of subjects: 166
Study 16799212 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of cardiovascular disease in diabetes mellitus
Number of subjects: 8400000
Study 14630384 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach training
Number of subjects: 212
Study 14630384 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus telephone-based support
Number of subjects: 212
Study 14630384 — intervention group
Group type: COMPARATOR
Intervention: Written guidelines (controls)
Number of subjects: 212
Study 11237545 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate head-up tilt
Number of subjects: 48
Study 11237545 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline head-up tilt
Number of subjects: 48
Study 11237545 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 48
Study 9246100 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic replacement of central venous catheters on a guide wire every 4 days
Number of subjects: 150
Study 9246100 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (one-way catheters left in situ as needed)
Number of subjects: 150